Advances in computational approaches in identifying synergistic drug combinations
暂无分享,去创建一个
Yi Sun | Zhi-Wei Cao | Kailin Tang | Zhen Sheng | Zuojing Yin | Z. Cao | Kailin Tang | Yi Sun | Zuojing Yin | Zhen Sheng
[1] B Xie,et al. Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. , 2009, Drug discovery today.
[2] Bo Zhang,et al. A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway , 2010, BMC Systems Biology.
[3] Xiaobo Zhou,et al. Systems Modeling of Anti-apoptotic Pathways in Prostate Cancer: Psychological Stress Triggers a Synergism Pattern Switch in Drug Combination Therapy , 2013, PLoS Comput. Biol..
[4] Peter M. A. Sloot,et al. Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time , 2010, PloS one.
[5] Tao Xu,et al. Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..
[6] Juanita Lopez,et al. Combine and conquer: challenges for targeted therapy combinations in early phase trials , 2017, Nature Reviews Clinical Oncology.
[7] Zhiwei Cao,et al. Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer , 2015, Nature Communications.
[8] Xing Chen,et al. ASDCD: Antifungal Synergistic Drug Combination Database , 2014, PloS one.
[9] Jun Zou,et al. Neighbor communities in drug combination networks characterize synergistic effect. , 2012, Molecular bioSystems.
[10] Sam Michael,et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.
[11] Jun Liu,et al. Fusion of core pathways reveals a horizontal synergistic mechanism underlying combination therapy. , 2011, European journal of pharmacology.
[12] Peter J. Park,et al. Systematic Identification of Synergistic Drug Pairs Targeting HIV , 2012, Nature Biotechnology.
[13] J. Lehár,et al. Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.
[14] M. Held,et al. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. , 2013, Cancer discovery.
[15] Feng Xu,et al. Therapeutic target database update 2014: a resource for targeted therapeutics , 2013, Nucleic Acids Res..
[16] Susanne May,et al. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance , 2008, AIDS.
[17] Casey S Greene,et al. Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivity , 2013, Genome Medicine.
[18] Kenneth C. Anderson,et al. Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma , 2010, Molecular Cancer Therapeutics.
[19] Paola Lecca,et al. Biological network inference for drug discovery. , 2013, Drug discovery today.
[20] Xing-Ming Zhao,et al. Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..
[21] Igor Goryanin,et al. Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition. , 2011, Cellular signalling.
[22] R Yuan,et al. Traditional Chinese medicine: an approach to scientific proof and clinical validation. , 2000, Pharmacology & therapeutics.
[23] Xing-Ming Zhao,et al. Exploring drug combinations in genetic interaction network , 2012, BMC Bioinformatics.
[24] Cheng Luo,et al. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors. , 2013, Bioorganic & medicinal chemistry.
[25] Yi Xiong,et al. PDC-SGB: Prediction of effective drug combinations using a stochastic gradient boosting algorithm. , 2017, Journal of theoretical biology.
[26] Yiling Lu,et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.
[27] Jörn Lötsch,et al. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. , 2011, Drug discovery today.
[28] Andreas Bender,et al. Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. , 2016, Drug discovery today.
[29] Jianfeng Pei,et al. Understanding traditional Chinese medicine anti-inflammatory herbal formulae by simulating their regulatory functions in the human arachidonic acid metabolic network. , 2013, Molecular bioSystems.
[30] Pablo Carbonell,et al. Overcoming drug resistance through in silico prediction. , 2014, Drug discovery today. Technologies.
[31] Xiaobo Zhou,et al. Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach , 2014, Bioinform..
[32] Xin Chen,et al. DCDB 2.0: a major update of the drug combination database , 2014, Database J. Biol. Databases Curation.
[33] David J Harrison,et al. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. , 2012, Cellular signalling.
[34] Xiaobo Zhou,et al. Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts , 2015, PloS one.
[35] Joshua M. Korn,et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.
[36] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[37] Devadasan Velmurugan,et al. Identification of Natural Compound Inhibitors for Multidrug Efflux Pumps of Escherichia coli and Pseudomonas aeruginosa Using In Silico High-Throughput Virtual Screening and In Vitro Validation , 2014, PloS one.
[38] Yang Xie,et al. A community computational challenge to predict the activity of pairs of compounds , 2014, Nature Biotechnology.
[39] Victor Guallar,et al. Computational Prediction of HIV-1 Resistance to Protease Inhibitors , 2016, J. Chem. Inf. Model..
[40] Yair Benita,et al. An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies , 2016, Molecular Cancer Therapeutics.
[41] C. Sander,et al. Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.
[42] Bo Zhang,et al. Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.
[43] Zsolt Bikádi,et al. Predicting substrates of the human breast cancer resistance protein using a support vector machine method , 2013, BMC Bioinformatics.
[44] P. Aloy,et al. Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer. , 2017, Cancer research.
[45] Jun Liu,et al. Convergent and Divergent Pathways Decoding Hierarchical Additive Mechanisms in Treating Cerebral Ischemia–Reperfusion Injury , 2014, CNS neuroscience & therapeutics.
[46] Remy Chait,et al. Optimal Drug Synergy in Antimicrobial Treatments , 2010, PLoS Comput. Biol..
[47] Laleh Soltan Ghoraie,et al. Predictive approaches for drug combination discovery in cancer , 2018, Briefings Bioinform..
[48] U. Alon,et al. Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.
[49] Concha Bielza,et al. Predicting human immunodeficiency virus inhibitors using multi-dimensional Bayesian network classifiers , 2013, Artif. Intell. Medicine.
[50] I. Melero,et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.
[51] Xing-Ming Zhao,et al. The drug cocktail network , 2012, BMC Systems Biology.
[52] Paul Shinn,et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.
[53] Michelle S. Scott,et al. Chemogenomic profiling predicts antifungal synergies , 2009, Molecular systems biology.
[54] Chris Sander,et al. Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets , 2013, Science Signaling.
[55] Hao Wang,et al. Network Understanding of Herb Medicine via Rapid Identification of Ingredient-Target Interactions , 2014, Scientific Reports.
[56] Kyoung Mii Park,et al. CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules , 2012, PloS one.
[57] Adam L Cohen,et al. A genomic approach to predict synergistic combinations for breast cancer treatment , 2011, The Pharmacogenomics Journal.
[58] Giovanni Ulivi,et al. Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization , 2009, Bioinform..
[59] Xing Chen,et al. NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning , 2016, PLoS Comput. Biol..
[60] STC Wong,et al. DIGRE: Drug-Induced Genomic Residual Effect Model for Successful Prediction of Multidrug Effects , 2015, CPT: pharmacometrics & systems pharmacology.
[61] Oliver Werz,et al. Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.
[62] Jianxin Chen,et al. Large-scale exploration and analysis of drug combinations , 2015, Bioinform..
[63] Lei Huang,et al. DrugComboRanker: drug combination discovery based on target network analysis , 2014, Bioinform..
[64] Michael Costanzo,et al. Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.
[65] R. Sun,et al. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm , 2008, Proceedings of the National Academy of Sciences.
[66] Karen A. Ryall,et al. Systems biology approaches for advancing the discovery of effective drug combinations , 2015, Journal of Cheminformatics.
[67] Soo-Ah Park,et al. Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim , 2014, BMC Cancer.
[68] Paul Shinn,et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia , 2015, Retrovirology.
[69] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[70] Ge-Fei Hao,et al. Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors. , 2010, The journal of physical chemistry. B.
[71] Matthias Rarey,et al. Beyond the Virtual Screening Paradigm: Structure-Based Searching for New Lead Compounds , 2009, J. Chem. Inf. Model..
[72] Simon P. Langdon,et al. Customizing the Therapeutic Response of Signaling Networks to Promote Antitumor Responses by Drug Combinations , 2014, Front. Oncol..
[73] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[74] István A. Kovács,et al. Drug-therapy networks and the prediction of novel drug targets , 2008, Journal of biology.